U.S. Global Investors (USGI)’s Alexion Pharmaceuticals ALXN Stock Holding History

U.S. Global Investors (USGI)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-6,000	Closed	-$1.11M	–	377
2014 Q4	$1.11M	Buy	6,000 +2,000	+50%	+$371K	0.3%	78
2014 Q3	$663K	Hold	4,000	–	–	0.19%	127
2014 Q2	$625K	Hold	4,000	–	–	0.13%	132
2014 Q1	$609K	Buy	+4,000	New	+$636K	0.1%	169

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

U.S. Global Investors (USGI)'s ALXN Position: Q1 2015 in Review

U.S. Global Investors (USGI) sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 6,000 shares — an estimated $1.11M sold.

U.S. Global Investors (USGI) first reported a position in ALXN in Q1 2014 and held it in 4 quarters. The position peaked at $1.11M in Q4 2014. 566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

U.S. Global Investors (USGI) reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
U.S. Global Investors (USGI) sold 6,000 Alexion Pharmaceuticals shares in Q1 2015, an estimated $1.11M.
U.S. Global Investors (USGI) first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 4 quarters.
U.S. Global Investors (USGI)'s Alexion Pharmaceuticals position peaked at $1.11M in Q4 2014.
566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on U.S. Global Investors (USGI)'s 13F filing for Q1 2015, filed 15 May 2015.